Spino Modulation, a subsidiary of Spinologics, received FDA’s Breakthrough Device Designation for its MIScoli™ system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents.
MIScoli is one of a few VBT devices that are under investigation, or limited market release, in many countries. Various medical device developers have committed to developing VBT solutions to serve an unmet need in the scoliosis surgical treatment market.
VBT is an alternative to spine fusion, today’s standard of care when adolescents need a surgical intervention to correct a curvature of the spine. Patients, and their parents, are looking for treatment options that are less traumatic than fusion, which is associated with long in hospital and at-home recovery times, growth and mobility restrictions, longer term pain and narcotics requirements and significant surgical scars.
Source: Spinologics
Spino Modulation, a subsidiary of Spinologics, received FDA's Breakthrough Device Designation for its MIScoli™ system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents.
MIScoli is one of a few VBT devices that are under investigation, or limited market release, in many countries. Various medical...
Spino Modulation, a subsidiary of Spinologics, received FDA’s Breakthrough Device Designation for its MIScoli™ system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents.
MIScoli is one of a few VBT devices that are under investigation, or limited market release, in many countries. Various medical device developers have committed to developing VBT solutions to serve an unmet need in the scoliosis surgical treatment market.
VBT is an alternative to spine fusion, today’s standard of care when adolescents need a surgical intervention to correct a curvature of the spine. Patients, and their parents, are looking for treatment options that are less traumatic than fusion, which is associated with long in hospital and at-home recovery times, growth and mobility restrictions, longer term pain and narcotics requirements and significant surgical scars.
Source: Spinologics
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.